Tag: Drug Manufacturing

Dalkhimpharm conducts large-scale modernization

dalkhimfarm
A large-scale modernization aimed at expanding production facilities and manufacturing competitive products has began at Dalkhimpharm plant.

French CDMO will manufacture innovative cancer treatments for Novartis

novartis
Novartis signed an agreement with CELLforCURE to produce innovative cancer treatments known as CAR-T therapies (chimeric antigen receptor T-cells) at the bioproduction site based in Les Ulis (Essonne).

South Korean company acquires AMPAC Fine Chemicals

api
SK Holdings, the parent company of South Korea’s third-largest conglomerate SK Group, announced that it has acquired a 100 percent stake in AMPAC Fine Chemicals, a US-based contract manufacturer of APIs.

Kazakh pharma manufacturers will receive a 10-year guaranteed market

kelun-kazakhstan
SK-Pharmacy LLC, the single distributor in Kazakhstan, announced a competitive bidding for long-term contracts with domestic manufacturers.

Boehringer Ingelheim boosts its drug manufacturing capabilities in China

boehringer-ingelheim
Boehringer Ingelheim, a leading contract manufacturer for biopharmaceutical medicines, has rounded off its full-service capabilities for customers with a new filling line at Shanghai, China.

DSM Sinochem Pharmaceuticals to be bought by Bain Capital

DSM Sinochem Pharmaceuticals
Bain Capital Private Equity, a leading global private investment firm, announced that it has signed a definitive agreement to acquire DSM Sinochem Pharmaceuticals (DSP).

Fermion launched a new API manufacturing facility in Finland

api
Fermion Oy, a privately held Finnish manufacturer of active pharmaceutical ingredients (APIs), has reached a significant milestone in its investment project by entering the commissioning phase of its new plant in Hanko (Finland).

Russian pharmaceutical manufacturers stake on prescription products

manufacturing
In the first five months of 2018, Russia produced medicinal products worth 132.2 billion rubles (in ex works prices). Compared to the same period of the last year, the dynamics are still negative.

Authorities are preparing additional preferences for Russian pharma manufacturers

vaccines
A relevant draft order on additional preferences for manufacturers is being prepared for state registration in the Ministry of Justice, announced the press service of the Russian Ministry of Industry and Trade.

WuXi Biologics and Harbour BioMed entered a manufacturing partnership

molecules pic
WuXi Biologics and Harbour BioMed announced an initial strategic collaboration for the development and manufacturing of Harbour’s leading HCAb antibody.

Output of Kaluga cluster may exceed 100 billion rubles by 2020

astrazeneca
By 2020, Kaluga pharmaceutical cluster will triple its output compared to 2017, announced Anatoly Sotnikov, Director of the regional Innovative Development Agency.

Novacap acquires PCI Synthesis CDMO

research
Novacap announced that it has signed an agreement to acquire Boston-based PCI Synthesis, a leading U.S. pharmaceutical contract development and manufacturing organization (CDMO).

CASI Pharmaceuticals partnered with Yiling Wanzhou International Pharmaceutical

drug development
CASI Pharmaceuticals, a US-based biopharmaceutical company, will expand its presence in China by entering into a long-term manufacturing agreement with China’s Yiling Wanzhou International Pharmaceutical Co. Ltd

CellGenix expands its German facility

pharma
CellGenix, a global manufacturing leader of GMP-grade raw materials for cell therapy, gene therapy and tissue-engineered products, successfully completed the first phase of its headquarters’ expansion.

Output by NPO Biomed immunobiological products exceeded 6 million packages

biomed
NPO Biomed, the largest developer and manufacturer of immunobiological products in the Perm Krai, an affiliate of NPO Microgen of Nacimbio Holding Company, part of Rostec Corporation, marked its 120th anniversary.

Biokhimik enters Southeast Asia market

biokhimik
Biokhimik, a Saransk-based plant producing more than 100 medicines, wants to start supplying its products to Vietnam in late 2018 - early 2019 after obtaining the registration certificates.